CA
NZ
UK
AU
IND
US
Investors are weighing the earnings shortfall against a strong rally and a 12% short‑interest position that implies modest pressure to cover. The contrast between the negative EPS and the market’s bullish price action underscores theVolatilityinherent in biotech valuations.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced an $820 million upfrontAcquisitionof Actio Biosciences, with an additional $500 million possible contingent payout. The transaction adds ABS‑1230, a KCNT1 ion‑channel inhibitor, to the company’s rare epilepsyFranchise. The deal deepens Jazz’s pipeline as it seeks to diversify beyond its …
Microbot Medical Inc. (Nasdaq: MBOT), a company specializing in robotic medical devices, has announced a new material agreement. This key development indicates a significant strategic move designed to strengthen the company’s operational capabilities and market positioning within the competitive healthcare technology sector. The agreement …
MoonLake Immunotherapeutics (Nasdaq: MLTX) announced that 42.1% of patients in its Phase 3 IZAR‑1 trial achieved an ACR50 response at Week 16, while secondary outcomes reached 66.5% ACR20, 41.2% MDA and 61% PASI90. In the same quarter,Earnings Per Sharecame in at $‑0.98 versus a …
Neogen Corp (Nasdaq: NEOG) has announced a significant change in itsLeadership, with Thierry Bernard resigning from theBoard of Directors. This move may impact investor confidence in the company, given its recent performance. Shares are up 63.9% year-to-date and 17.6% over the past month, with …
This marks a significant turnaround for the company, ensuring its continued listing on theNasdaq Capital Market. Previously, on March 5, 2026, Niki BioSolutions had received a deficiency letter indicating its stock had fallen below the required threshold for over 30 consecutiveBusinessdays. This turnaround directly …
Oruka Therapeutics priced an upsized $700 million public offering, raising cash and marketable securities to $1.1 billion, enough to fund operations through aBiologicsLicense Application filing for its lead candidate. TheCapitalinfusion eases financing pressure and positions the company toCapitalizeon forthcoming Phase‑3 data, supporting a clearer …
Park Dental Partners, Inc. (Nasdaq: PARK) has announced an agreement to acquire Village Family Dental for a total consideration of $39.1 million, marking a significant move into North Carolina's dental services market. This transaction will enhance Park Dental's position by incorporating Village Family Dental's …
CTT Pharmaceutical Holdings' CEO has acquired $500 worth of CTTH stock, marking a significant personal investment that may reflect a positive outlook for the company. This insider buying activity could enhance investor confidence, potentially bolstering market interest and share prices. As stock purchases by …
Entera Bio Ltd. (Nasdaq: ENTX) has raised $275 million in an oversubscribed private placement, providing the company with sufficient funds to advance its lead candidate, EB613, an oral anabolic tablet for osteoporosis, through a potentialNew Drug Application (NDA)submission. Comparative anchor: ENTX reported EPS of …
Please wait processing your request...